Report Highlights

South Korea Gastritis Treatment: Competitive Overview

South Korea's gastritis treatment market operates under a moderately concentrated structure, with the top five players — Daewoong Pharmaceutical, Yuhan Corporation, HK inno.N, Takeda Korea, and Dong-A ST — collectively controlling an estimated 58% of prescription-based revenue. Domestic manufacturers hold a structural advantage rooted in Korea's national health insurance reimbursement system, which incentivizes generic substitution and gives locally manufactured formulations a decisive cost edge at the pharmacy counter. Multinational companies including AstraZeneca Korea and Eisai Korea retain presence primarily in the hospital channel and specialized gastroenterology clinics, where brand equity and clinical familiarity still influence formulary decisions.

Competitive advantage in this market is determined by three country-specific factors: speed of biosimilar and generic listing on the Health Insurance Review and Assessment Service (HIRA) approved drug registry, co-marketing relationships with gastroenterology opinion leaders at Korea's major academic medical centers such as Asan Medical Center and Samsung Medical Center, and access to the community pharmacy network where the majority of gastritis prescriptions are dispensed. Companies that combine a broad generic PPI portfolio with a next-generation acid blocker entry — specifically potassium-competitive acid blockers (P-CABs) — are best positioned to dominate across both volume and value segments simultaneously.

Demand Drivers Shaping Gastritis Treatment in South Korea

South Korea's exceptionally high rate of gastric cancer awareness and mandatory national screening programs are the single most powerful demand driver in this market. The National Cancer Screening Program mandates gastric endoscopy for all adults over 40 every two years, generating a continuous diagnostic pipeline that converts asymptomatic H. pylori carriers into active gastritis treatment cases. Daewoong and Yuhan benefit most from this screening-to-prescription pipeline because their H. pylori eradication kits are pre-positioned in the clinic-dispensing protocols used by the majority of primary care and gastroenterology outpatient settings. This institutionalized screening infrastructure creates a recurring, policy-guaranteed demand floor that insulates market leaders from typical demand volatility.

Two additional drivers compound market growth. First, Korea's rapidly aging population — with adults over 65 projected to comprise 20% of the total population by 2026 — expands the chronic gastritis and NSAID-induced gastropathy patient pool, benefiting companies with established geriatric care channel relationships. Second, growing consumer awareness of gut health, amplified through Korea's highly active digital health media ecosystem, is driving OTC antacid and H2 blocker consumption above historical baselines. Boryung Pharmaceutical and Chong Kun Dang, both with strong OTC pharmacy footprints, are capturing incremental volume from this self-medication trend, which operates largely outside national insurance reimbursement and therefore at superior margin levels.

Competitive Restraints and Market Challenges

South Korea's pharmaceutical price regulation presents the most structurally constraining competitive challenge in this market. HIRA's mandatory drug price renegotiation mechanism — triggered when a product's annual sales exceed a defined threshold — has repeatedly cut reimbursement prices for top-selling PPIs by 10–20% following commercial success reviews. This creates a perverse dynamic where achieving volume leadership in the branded segment directly triggers revenue-diluting price cuts, discouraging the sustained promotional investment that multinational companies require to justify local commercial infrastructure. AstraZeneca Korea's esomeprazole franchise experienced two consecutive reimbursement price reductions between 2019 and 2023, materially impacting the profitability of its gastritis portfolio.

Antibiotic resistance to clarithromycin — a cornerstone of first-line H. pylori eradication therapy in Korea — is an escalating clinical and competitive challenge. Clarithromycin resistance rates in Korean H. pylori strains have climbed above 30%, prompting the Korean Society of Helicobacter and Upper Gastrointestinal Research to revise treatment guidelines toward bismuth-based quadruple therapy and vonoprazan-containing regimens. This guideline shift disrupts the established competitive positions of companies whose product portfolios are heavily weighted toward legacy triple therapy kits and creates an urgent reformulation or portfolio expansion imperative. Smaller domestic manufacturers lacking vonoprazan licensing or bismuth compound supply chains face a meaningful risk of formulary displacement over the 2025–2028 period.

Growth Opportunities for Market Players

The P-CAB segment represents the highest-value growth opportunity in the South Korean gastritis treatment market, with vonoprazan-based regimens positioned to replace legacy PPI combinations across both H. pylori eradication and erosive esophagitis maintenance indications. HK inno.N's domestically developed tegoprazan (Tegopen) is the most strategically significant competitive development in recent years — it is the first Korean-origin P-CAB approved by the Ministry of Food and Drug Safety (MFDS), and its commercial performance directly challenges Takeda's imported vonoprazan. HK inno.N is actively exporting tegoprazan to 30+ countries, reinforcing domestic brand prestige and enabling premium reimbursement negotiating leverage with HIRA that generic PPI manufacturers cannot replicate.

A second material opportunity lies in the convergence of digital therapeutics and gastroenterology care management. Korea's Digital Therapeutics Act, enacted in 2023, creates a regulatory pathway for software-based therapeutic adjuncts targeting chronic gastritis management — including H. pylori recurrence monitoring and medication adherence tools. Pharmaceutical companies that move first to co-develop or acquire digital therapeutic companions to their drug portfolios can build patient retention infrastructure that pure generic competitors cannot easily replicate. Daewoong's existing digital health investment activity and partnerships with Korean health IT firms position it as the most likely domestic first-mover in this converged gastritis management segment.

Market at a Glance

Leading Market Participants

• Daewoong Pharmaceutical
• Yuhan Corporation
• HK inno.N
• Dong-A ST
• Boryung Pharmaceutical
• Chong Kun Dang
• Takeda Korea
• AstraZeneca Korea
• Eisai Korea
• Hanmi Pharmaceutical

Regulatory and Policy Environment

The Ministry of Food and Drug Safety (MFDS) governs drug approval in South Korea, with gastritis treatment products subject to standard new drug application pathways that align broadly with ICH guidelines, enabling multinational submissions without extensive reformulation. However, the competitive battleground is shaped more acutely by HIRA's reimbursement listing process, which applies a cost-effectiveness threshold model that systematically favors generic entrants and domestically priced molecules. The Drug Benefit Coverage Expansion Policy, updated in 2022, broadened reimbursable H. pylori eradication indications to include non-ulcer functional dyspepsia, materially expanding the addressable prescription pool and directly benefiting companies with pre-listed eradication regimen products.

Korea's National Health Insurance Act mandates generic substitution at the pharmacy level unless a physician explicitly designates brand-only dispensing, which structurally suppresses branded PPI volume in the community setting. The Pharmaceutical Affairs Act amendments of 2021 also tightened post-market surveillance requirements for antibiotic-containing eradication kits, increasing compliance costs for manufacturers of clarithromycin-based triple therapy products. These regulatory cost pressures disproportionately affect smaller domestic manufacturers and create consolidation pressure within the eradication kit segment, where the top three suppliers — Daewoong, Yuhan, and Dong-A ST — are best equipped to absorb compliance overhead while maintaining competitive pricing.

Competitive Outlook for South Korea Gastritis Treatment

By 2032, the competitive structure of South Korea's gastritis treatment market will be defined by a two-tier landscape: a premium P-CAB tier dominated by HK inno.N's tegoprazan and Takeda's vonoprazan competing on clinical differentiation and reimbursement access, and a high-volume generic PPI tier where Daewoong, Yuhan, and Hanmi compete aggressively on price and distribution efficiency. The transition from triple therapy to vonoprazan or bismuth quadruple therapy as the first-line H. pylori standard of care will accelerate portfolio rebalancing across all major players, with companies slow to establish P-CAB commercial infrastructure losing meaningful prescription share in the gastroenterology specialist channel where new guideline adoption is fastest.

Market consolidation through licensing agreements and domestic M&A activity is expected to intensify between 2025 and 2028, as mid-tier domestic manufacturers without P-CAB assets seek alignment with players holding next-generation pipeline access. Chong Kun Dang and Boryung are the most likely acquisition or co-promotion targets given their established OTC and community pharmacy networks, which larger prescription-focused competitors lack. The entry of two or more Korean generic tegoprazan or vonoprazan equivalents after patent expiration — estimated post-2028 — will compress the P-CAB premium window and shift the next competitive battleground toward combination therapies, digital adherence tools, and microbiome-targeting gastritis adjuncts where no single player holds a commanding position today.